Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $257,550.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,151 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $50.00, for a total transaction of $257,550.00. Following the completion of the transaction, the director now owns 300,695 shares in the company, valued at approximately $15,034,750. This represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Pro-Dex Stock Performance

Shares of Pro-Dex stock opened at $49.85 on Thursday. The stock has a market capitalization of $162.56 million, a price-to-earnings ratio of 24.80 and a beta of 0.68. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The business has a 50-day moving average of $39.75 and a 200 day moving average of $38.74. Pro-Dex, Inc. has a 12 month low of $16.84 and a 12 month high of $59.60.

Pro-Dex (NASDAQ:PDEX) last posted its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, sell-side analysts forecast that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

Hedge Funds Weigh In On Pro-Dex

Several institutional investors have recently modified their holdings of the business. FMR LLC boosted its holdings in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares during the period. Bank of New York Mellon Corp acquired a new stake in Pro-Dex in the 4th quarter valued at about $202,000. Trexquant Investment LP purchased a new position in shares of Pro-Dex in the 4th quarter valued at about $252,000. Integrated Quantitative Investments LLC acquired a new position in shares of Pro-Dex during the fourth quarter worth about $254,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Pro-Dex during the fourth quarter worth approximately $255,000. Institutional investors and hedge funds own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.